Clinical Trial Search

Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15

Primary: Need for Dialysis in the First 30 Days Post-transplant — 10; 10 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 139; 0; 6; 6 Participants

Primary: Medline 2% CHG Cloth Dosage of Coverage Area — 0.0081 g/cm^2

Primary: Change in PGC-1alpha RNA Expression — -0.02190716; 0.3160562; 0.07414876; 0.4800263 Log 2 fold change

Primary: Numerical Pain Intensity — 6.03; 6.11; 6.24; 5.97 score on a scale — p=0.78

Primary: Change of Pain-on-movement (POM) Compared to Baseline — -50.7; -21.6 units on a scale — p=< 0.0001

Primary: Change in ALSFRS-R Slope — 0.229; 0.224 ALSFRS-R points per week — p=0.984

Primary: Number of Participants Who Experienced a Solicited Adverse Event (AE) Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2 — 9; 5; 253…

Primary: Progression-free Survival at 1 Year — 33.3 proportion of progression-free pts

Primary: Percentage of Participants With Two-Year Disease-Free Survival (DFS) — 56.6; 62.4 percentage of participants

Primary: Highest Dose of Peanut That is Tolerated During Oral Food Challenge — 29; 4,044 mg — p=0.002

Primary: Average Gait Speed — 0.973 meters/second — p=0.015

Primary: Number of Myelomonocytic Cells in the Blood — 3197; 4340; 3390; 3241 cells per microliter (µL)

Primary: Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans — 1.09 standardized uptake value ratio